Granulomatous cutaneous T-cell lymphoma in a patient with atage IVB of mycosis fungoides: a case report and literature review
-
By
-
Zhu Lin
-
Jing Xue
-
Guozeng Ye
-
Shuang Li
-
Tingzhi Liu
-
Jiping Lang
-
Zhixin Zheng
-
Xiaoyan Li
-
Qinbo Wang
-
Junrong Chen
-
June 10, 2026
-
Clinical Scorecard: Granulomatous Mycosis Fungoides in a Stage IVB Patient: A Case Study and Review of Existing Literature
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Originates from memory helper T cells; characterized as a variant of CD4+ non-Hodgkin lymphoma with potential for aggressive behavior. |
| Target Population | |
| Care Setting | |
Key Highlights
- GMF presents with heterogeneous clinical and histological features.
- Initial misdiagnosis as psoriasis can occur due to symptom overlap.
- Biopsies are crucial for differentiating GMF from other inflammatory conditions.
- Advanced stages may involve lymph node and visceral involvement.
- Immunohistochemical evaluations are essential for accurate diagnosis.
- Distinguishing GMF from other granulomatous diseases is critical for management.
Guideline-Based Recommendations
Diagnosis
- Perform cutaneous biopsies to confirm GMF and differentiate from other conditions.
Management
- Consider treatment options such as topical therapies, phototherapy, or systemic agents based on the stage and presentation of GMF.
Monitoring & Follow-up
- Regular follow-up for disease progression and response to treatment.
Risks
- Potential for misdiagnosis leading to inappropriate treatment.
Patient & Prescribing Data
Previous treatments included adalimumab, which exacerbated symptoms; consider alternative therapies that may be more effective.
Clinical Best Practices
- Utilize immunohistochemical markers for accurate diagnosis.
- Be aware of the clinical presentation similarities between GMF and other skin disorders.
- Monitor for systemic involvement in advanced stages.
- Encourage interdisciplinary collaboration for complex cases.
Related Resources & Content
